News

Gilead has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two mid-stage trials of ...
Shares of Gilead Sciences Inc. GILD rose 1.60% to $107.62 Thursday, on what proved to be an all-around great trading session ...
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
Before Gilead’s rise, the world in The Handmaid’s Tale was already falling apart. Food shortage, political unrest, environmental disasters — it was all there, bubbling just under the surface.
Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...
Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...
A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...